« Previous
Next »
Urology
Volume 64, Issue 2
, Pages 292-297
, August 2004
Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older
References
-
.
A comparison of radiation and surgery for cancer of the bladder.
JAMA. 1947;134:501–507
- . Treatment of patients with carcinoma of the bladder. JAMA. 1951;145:295–301
- . Radical cystectomy for carcinoma of the bladder. Br J Urol. 1978;50:492–495
- . Cystectomy and urinary diversion. J Urol. 1966;96:714–717
- . Radical total cystectomy for cancer of the bladder (230 consecutive cases five years later). J Urol. 1962;87:853–868
- Radical cystectomy in the treatment of invasive bladder cancer (long-term results in 1,054 patients). J Clin Oncol. 2001;19:666–675
- . Complications of radical cystectomy and urinary diversion (a retrospective review of 675 cases in 2 decades). J Urol. 1992;148:1401–1405
- . Cystectomy and urinary diversion (a safe procedure for elderly patients). Urology. 1983;21:17–19
- . Cystectomy and urinary diversion in patients eighty years old or older. Urology. 1982;19:139–142
- A multicenter study of the morbidity of radical cystectomy in select elderly patients with bladder cancer. J Urol. 2002;167:1325–1328
- Radical cystectomy for elderly patients with bladder carcinoma (an updated experience with 404 patients). Cancer. 1998;83:141–147
- Radical cystectomy for invasive bladder cancer in the octogenarian. Oncol Rep. 2001;8:723–726
- Radical cystectomy in the octogenarian. J Urol. 1997;158:2113–2117
- Is it justified to avoid radical cystoprostatectomy in elderly patients with invasive transitional cell carcinoma of the bladder?. Cancer. 1993;71:3098–3101
- . Factors influencing aggressive therapy for bladder cancer (an analysis of data from the SEER program). J Urol. 2003;170:1765–1771
- Patterns of care for the treatment of bladder cancer. J Urol. 2003;169:1697–1701
-
AJCC Cancer Staging Handbook.
5th ed. Philadelphia: Lippincott-Raven; 1997;
pp 223–226
☆ J. E. Montie is a study investigator funded by AstraZeneca. J. T. Wei is a paid consultant to Sanofi Synthelabo.
PII: S0090-4295(04)00406-6
doi: 10.1016/j.urology.2004.03.034
© 2004 Elsevier Inc. All rights reserved.
« Previous
Next »
Urology
Volume 64, Issue 2
, Pages 292-297
, August 2004
